$GLSI

Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy combining the GP2 peptide with GM-CSF. Its Phase III Flamingo-01 trial evaluates the treatment in HER2/neu-positive breast cancer patients at high risk of recurrence who have completed trastuzumab-based therapy. The company also reports completed Phase I and Phase IIb trials of GP2-based treatments. GP2 is administered with GM-CSF by intradermal injection, and the company depends on third-party manufacturers for materials and clinical-trial product. Greenwich LifeSciences holds exclusive worldwide licensed rights to patents and applications covering uses of GP2 to target HER2/neu-expressing cancers. It has no sales, marketing or distribution strategy for GP2 while the product remains in clinical development. The company is headquartered in Stafford, Texas.

5
0
1

No SEC Form 4 filings for $GLSI in the last 30 days.

See all $GLSI insider activity →

Biotech Stocks To Watch: SLS +160%, AYTU +48%, GLSI +32%, GLAS +24%

SELLAS Life Sciences (SLS) rose 160% after its cancer vaccine trial met primary endpoint, Aytu BioPharma (AYTU) gained 48% on a $56M acquisition deal, Glass House Brands (GLAS) advanced 24% on strong revenue and production, and Greenwich LifeSciences (GLSI) climbed 32% after breast cancer program abstracts were accepted for presentation.

Greenwich LifeSciences Stock Up 23% On Immunotherapy Trial Update

Greenwich LifeSciences (GLSI) shares rose 23% to $16.92 after the company announced two abstracts from its Phase III FLAMINGO-01 breast cancer immunotherapy trial were accepted for the 2026 SABCS. The stock's 52-week range is $7.78 to $34.10.

GLSI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning GLSI (Greenwich LifeSciences, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 1 bearish.

Recent GLSI coverage spans market movers, financial news and earnings.

What's driving GLSI

  • HC Wainwright & Co. kept its Buy rating on Greenwich LifeSciences and increased its price target to $70 from $69, suggesting a 274.3% upside from the Nov 17 close of $18.70.

    tradingview.com · Nov 18, 2026

  • Conference acceptance is a positive visibility catalyst for ongoing Phase 3 program data, but it is not the data release itself.

    rttnews.com · Nov 17, 2026

  • Accepted SABCS abstracts for its Phase III FLAMINGO-01 program is a near-term positive catalyst that can extend momentum and raise probability of further clinical visibility.

    rttnews.com · Nov 17, 2026

  • Loss widening and cash need increase near-term financing risk, while Phase III expansion is the main offsetting catalyst.

    tradingview.com · Nov 16, 2026

  • Positive trial results are likely to lift GLSI stock as investors anticipate regulatory approval and market potential.

    finanznachrichten.de · Nov 13, 2026

AlphAI scores every news story that mentions GLSI with an AI model for sentiment and relevance, and aggregates insider trades from Greenwich LifeSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GLSI

Score

Greenwich LifeSciences 3Q 2026: EPS ($0.4) — 10-Q Summary

Greenwich LifeSciences reported no revenue, with a net loss of $5.81M and EPS of -$0.40 in Q3 2026. R&D costs rose 67% due to clinical expenses, while G&A costs fell 12%. The company is expanding its Phase III trial for GLSI-100 globally. Cash reserves were $5.9M, but additional capital is needed for long-term operations, according to the company.

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

Why is Greenwich LifeSciences stock rallying today?

Greenwich LifeSciences Inc (GLSI) stock rose 6.4% to $16.29 in pre-market trading. The company reported Q2 2026 EPS of -$0.27, an improvement from the prior year. Positive clinical trial results, regulatory approvals, and a raised price target by HC Wainwright contributed to the rally. The broader market also showed gains, benefiting small-cap biotech stocks like GLSI.

After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Related tickers